AMRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Amneal Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$19.36+0.18 (+0.94%)
Close on Oct 19, 2026
- Market cap
- $6.35B
- P/E (TTM)
- 39.5
- Dividend yield
- –
Amneal Pharmaceuticals, Inc. revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Affordable Medicines | $1.75B | $1.69B | $1.47B | $1.43B | – | – | – | – | – | – | 57.8% | +3.6% |
| AvKARE | $744.73M | $662.95M | $531.75M | $406.11M | $349.01M | $293.75M | – | – | – | – | 24.7% | +12.3% |
| Specialty | $528.51M | $445.75M | $390.46M | $374.12M | $378.32M | $355.57M | $317.53M | $223.96M | $0 | $0 | 17.5% | +18.6% |
| Affordable Medicines | – | – | $1.47B | $1.43B | $1.37B | $1.34B | $1.31B | $1.44B | $1.03B | $1.02B | – | – |
| Specialty | – | – | – | $374.12M | $378.32M | $355.57M | $317.53M | $223.96M | – | – | – | – |
| Av Kare | – | – | – | – | $349.01M | $293.75M | $0 | $0 | – | – | – | – |
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Affordable Medicines | $380.80M | $270.10M | $276.17M | $224.16M | – | – | – | – | – | – | +41.0% |
| Specialty | $116.00M | $113.58M | $65.30M | $72.59M | $56.42M | – | – | $55.56M | $0 | $0 | +2.1% |
| AvKARE | $83.62M | $42.90M | $31.51M | $3.32M | $6.80M | -$7.66M | – | – | – | – | +94.9% |
| Affordable Medicines | – | – | $276.17M | $224.16M | $281.49M | $189.36M | -$133.15M | $162.90M | $307.50M | $334.17M | – |
| Specialty | – | – | – | $72.59M | $56.42M | $56.54M | $42.78M | $55.56M | – | – | – |
| Av Kare | – | – | – | – | $6.80M | -$7.66M | – | – | – | – | – |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diclofenac Sodium Gel | – | – | – | – | – | – | – | $103.13M | $94.40M | $71.67M | – | – |
| Yuvafem-Estradiol | – | – | – | – | – | – | – | $130.92M | $130.48M | $53.03M | – | – |
| Lidocaine | – | – | – | – | – | – | – | – | – | $121.83M | – | – |
| Metaxalone | – | – | – | – | – | – | – | – | – | $33.70M | – | – |
| Metformin ER | – | – | – | – | – | – | – | – | – | $33.42M | – | – |
| Aspirin Dipyridamole E R Capsul | – | – | – | – | – | – | – | $78.54M | $79.67M | – | – | – |
| Ranitidine | – | – | – | – | – | – | – | – | $31.28M | – | – | – |
| Oseltamivir | – | – | – | – | – | – | – | – | $37.24M | – | – | – |
| Royalties | – | – | – | – | – | – | $2.86M | $294.00K | $12.52M | – | – | – |
| Epinephrine Auto-Injector (generic Adrenaclick) | – | – | – | – | – | – | – | $67.53M | – | – | – | – |
| Rytary | – | – | – | – | – | – | – | $95.54M | – | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | – | – | – | – | – | – | $1.60B | $1.60B | $946.60M | – | – | – |
| International and other | – | – | – | – | – | – | $20.60M | $59.70M | $74.54M | – | – | – |
From the segment and revenue-disaggregation notes of Amneal Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.